Sabrina M. Martucci-Johnson

https://www.linkedin.com/in/sabrina-johnson-27799829/ Sabrina is one of the most determined voices in women’s health, and one of the few willing to bet her career on it. In 2015, Sabrina founded Daré Bioscience (NASDAQ: DARE), a clinical-stage biopharmaceutical company built on a single, uncompromising premise: women deserve better. Not incrementally better. Categorically better. From contraception and menopause to vaginal health, sexual health, fertility, and infectious disease, Daré is closing the gaps that a generations-long underinvestment in women’s biology left behind. Under her leadership, Daré has built a capital-efficient pipeline powered by rigorous science, landmark non-dilutive funding — including grants from the Gates Foundation, ARPA-H, and NIH — and a dual-path commercialization strategy designed to get innovations to women faster. Sabrina brings rare range to this mission. She began her career as a research scientist at Baxter Healthcare working on the recombinant factor VIII program, then built operational and financial expertise across Advanced Tissue Sciences, Cypress Bioscience (NASDAQ: CYPB), the California Institute for Biomedical Research, and WomanCare Global. That combination of bench science, finance, and commercial execution informs how she builds: with rigor, urgency, and zero tolerance for the status quo.